Table 1 Description of study population by trial arm.
Trial arm | ||||
|---|---|---|---|---|
Characteristics | ||||
SOT | TIX/CIL | NMV/r | Total | |
N = 116 | N = 113 | N = 117 | N = 346 | |
Gender, n(%) | ||||
Female | 53 (45.7%) | 58 (51.3%) | 60 (51.3%) | 171 (49.4%) |
Ethnicity, n(%) | ||||
Caucasian | 111 (95.7%) | 110 (97.3%) | 114 (97.4%) | 335 (96.8%) |
Age, years | ||||
Median (IQR) | 69 (60, 76) | 65 (54, 76) | 66 (55, 78) | 66 (55, 76) |
> 65, n(%) | 67 (57.8%) | 52 (46.0%) | 60 (51.3%) | 179 (51.7%) |
Days from symptoms onset | ||||
Median (IQR) | 3 (2, 4) | 3 (2, 4) | 3 (2, 4) | 3 (2, 4) |
> 2, n(%) | 34 (30.1%) | 28 (25.5%) | 31 (27.4%) | 93 (27.7%) |
Comorbidities, n(%) | ||||
Diabetes | 10 (8.6%) | 5 (4.4%) | 11 (9.4%) | 26 (7.5%) |
Obesity (BMI > 30) | 25 (21.6%) | 26 (23.0%) | 19 (16.2%) | 70 (20.2%) |
CVD | 8 (6.9%) | 9 (8.0%) | 9 (7.7%) | 26 (7.5%) |
COPD | 4 (3.4%) | 11 (9.7%) | 9 (7.7%) | 24 (6.9%) |
Renal impairment | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 1 (0.3%) |
Haematological cancer | 7 (6.0%) | 5 (4.4%) | 3 (2.6%) | 15 (4.3%) |
Immunodeficiency | 8 (6.9%) | 8 (7.1%) | 8 (6.8%) | 24 (6.9%) |
Neurologic disease | 1 (0.9%) | 3 (2.7%) | 1 (0.9%) | 5 (1.4%) |
Other | 47 (40.5%) | 44 (38.9%) | 50 (42.7%) | 141 (40.8%) |
Vaccination, n(%) | ||||
> 2 doses | 110 (94.8%) | 105 (92.9%) | 111 (94.9%) | 326 (94.2%) |
SARS-CoV-2 variant, n(%) | ||||
Omicron BA.1 | 6 (5.2%) | 5 (4.4%) | 9 (7.7%) | 20 (5.8%) |
Omicron BA.2 | 62 (53.4%) | 61 (54.0%) | 57 (48.7%) | 180 (52.0%) |
Omicron BA.4/5 | 42 (36.2%) | 41 (36.3%) | 40 (34.2%) | 123 (35.5%) |
Omicron BQ.1 | 6 (5.2%) | 6 (5.3%) | 11 (9.4%) | 23 (6.6%) |
Viral load on NPS sample | ||||
L og2 scale, median (IQR) | 3.99 (3.82, 4.22) | 3.95 (3.76, 4.23) | 4.00 (3.79, 4.20) | 3.99 (3.78, 4.21) |
